Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

INTRODUCTION: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Jessica K., Martyanov, Viktor, Magro, Cynthia, Wildman, Horatio F., Wood, Tammara A., Huang, Wei-Ti, Crow, Mary K., Whitfield, Michael L., Spiera, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538758/
https://www.ncbi.nlm.nih.gov/pubmed/26283632
http://dx.doi.org/10.1186/s13075-015-0721-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538758/
https://www.ncbi.nlm.nih.gov/pubmed/26283632
http://dx.doi.org/10.1186/s13075-015-0721-3

Ejemplares similares